RT Journal Article
SR Electronic
T1 Pharmacoeconomics: friend or foe?
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP iii44
OP iii47
DO 10.1136/ard.2006.058602
VO 65
IS suppl 3
A1 M Drummond
YR 2006
UL http://ard.bmj.com/content/65/suppl_3/iii44.abstract
AB The financial constraints faced by most health systems today make it necessary for manufacturers of new, expensive drugs to demonstrate value for money. This paper describes the different types of economic evaluation; the increasing use of these analysis in decision making; their application to new drugs in the field of in rheumatoid arthritis; and the pros and cons of pharmacoeconomics studies from the perspective of the patients, the physicians, and the general population.